Dr. Karzai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
10 Center Drive
10/Room 12n226
Bethesda, MD 20892- Is this information wrong?
Education & Training
George Washington University School of Medicine and Health SciencesClass of 2005
Certifications & Licensure
MD State Medical License 2009 - 2024
VA State Medical License 2005 - 2009
DC State Medical License 2005 - 2009
Clinical Trials
- Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer Start of enrollment: 2019 Dec 04
Roles: Contact, Principal Investigator
- Precision-Based Genomics in Prostate Cancer Start of enrollment: 2021 Sep 14
Roles: Principal Investigator, Contact
- Men at High Genetic Risk for Prostate Cancer Start of enrollment: 2019 Mar 27
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients.David J Einstein, Jeanny B Aragon-Ching, Fatima Karzai, Ravi A Madan> ;Current Opinion in Oncology. 2024 May 1
- Increasing diversity in clinical trials: Demographic trends at the national cancer institute, 2005-2020.Nipp, R., Choradia, N., Karzai, F., Naqash, A., Gulley, J., Floudas, C.> ;Journal of the National Cancer Institute. 2024 Feb 19
- Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibition.Scott Wilkinson, Anson T Ku, Rosina T Lis, Isaiah M King, Daniel Low, Shana Y Trostel, John R Bright, Nicholas T Terrigino, Anna Baj, John M Fenimore, Chennan Li, BaoH...> ;Medrxiv. 2024 Feb 11
- Join now to see all
Journal Articles
- Tumor Cell Heterogeneity and Resistance; Report from the 2018 Coffey‐Holden Prostate Cancer Academy MeetingThomas A Hope, Kenneth J Pienta, Fatima Karzai, Simpa S Salami, Robert B Den, The Prostate
Press Mentions
Olaparib Shows Synergy with Durvalumab in mCRPCFebruary 9th, 2018
Olaparib, Durvalumab Combo Active in Prostate CancerFebruary 17th, 2017
Enzalutamide Gets Added Approval for Prostate Cancer That Hasn’t SpreadJanuary 7th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
